Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease

The Renal Lifecycle trial aims to investigate the effects of the SGLT2 inhibitor dapagliflozin compared with placebo on the incidence of kidney failure, heart failure, mortality and safety in three subgroups of patients with advanced CKD.

Authors

Institutions

Publication Details

Journal
Nephrology Dialysis Transplantation
Published
2025-03-06
DOI
https://doi.org/10.1093/ndt/gfaf046
Citations
15
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
19.42

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease

Dharmenaan Palamuthusingam, Nathan Brinkman, G. Breda, Emilie Mahieu et al.
15 citations
Nephrology Dialysis Transplantation
Diabetes Treatment and Management
19.42
article

Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease

Dharmenaan Palamuthusingam, Nathan Brinkman, G. Breda, Emilie Mahieu, Dennis A. Hesselink, Brendan Smyth, Rosemary Masterson, Ron T. Gansevoort, W Bakker, Michael Walsh, G. William Wong, J W Rood, Rob C.M. van Kruijsdijk, Werner Seeger, Anna Laura Herzog, Hemant Kulkarni, Femke Waanders, Michel P. Hermans, Henk Nijmeijer, WooJe Lee, Tom Dejagere, Marta Soler, Alexander F.L. Later, Akin Özyilmaz, Hiddo J.L. Heerspink, Christoph Wanner, Anna Buxeda Porras, Ronald van Etten, Eugenia Pedagogos, Paul Leurs, Joost C. van den Born, Margarida Marques, Marc Vervloet, Stefan R. A. Konings, Clare Arnott, Marc H. Hemmelder, Maria Isabel Troya Saborido, Vartika Srivastava, Martina Guthoff, Johannes Stegbauer, Beatriz Sánchez Álamo, Wim Lemahieu, Arnold H. Boonstra, Marga Eshuis, Muh Geot Wong, Manuel Macı́a, Stefan P. Berger, José Luis Górriz, R. Krishnasamy, Josep M. Cruzado, Angela Yee‐Moon Wang, Arjan M. van Alphen, Bernhard Banas, Thomas van Bemmel, Alferso C Abrahams, Matthias Girndt, J S Wiegersma, Dirk Kuypers, Michael Schömig, C. E. H. Siegert, Anita van Eck van der Sluijs, J J Huitema, Gert Meeus, Martin Zeier, Lily Jakulj, Frank Stifft, S. J. J. Logtenberg, M. Gelens, Klemens Budde, Sandrine Gaillard, Henk Boom, Shilpanjali Jesudason, Martin Busch, Nilda M. García, Julia Weinmann‐Menke, Jacqueline T. Jonker, J. Bayrak, Georg Schlieper, Dominique van Mil, Angela Makris, Ellen K. Hoogeveen, James Holt, Boon Wee Teo, Mario Schiffer, Asunción Sancho, Sunil V. Badve, Manon Schouten, Sander W.M. Keet, Aaltje Y Adema, Willem A. Bax, Peter T Luik, Aiko P. J. de Vries, Frank Strutz, K. Sreekanth, Karen Keung, Mercedes Salgueira, J Van der Heijden, Kate Wyburn, Joep van der Leeuw, Bernd Hohenstein, Gürbey Ocak, Alison E. Mather, Katrien François, Jeroen J P Slebe, Miriam Blanco, Juan Buades, Yumiao Liu, Peter van der Meer, Jeroen B. van der Net, Girish Scricant Talaulikar, Bernd Schröppel, EF de Maar, F Gonzales, Yvonne De Waal, M Munar, W Jansen, Mohamed Condé, M Goiciechea, L Siddiqi-Nadery, Tim C van Faassen
article en
15 citations

Abstract

The Renal Lifecycle trial aims to investigate the effects of the SGLT2 inhibitor dapagliflozin compared with placebo on the incidence of kidney failure, heart failure, mortality and safety in three subgroups of patients with advanced CKD.

Nephrology Dialysis TransplantationVol. 40(9)
Albert Schweitzer Hospital (GA), University Medical Center Groningen (NL), Radboud University Nijmegen (NL), University of Groningen (NL), Singapore General Hospital (SG), Leiden University Medical Center (NL), Maastricht University Medical Centre (NL), Erasmus MC (NL), Radboud University Medical Center (NL), University Medical Center Utrecht (NL), UNSW Sydney (AU), Maastricht University (NL), Albert Schweitzer Ziekenhuis (NL), Dianet (NL), The George Institute for Global Health (AU), Universitätsklinikum Würzburg (DE), INCLIVA Health Research Institute (ES), McMaster University (CA), KU Leuven (BE)
Changi General Hospital
Good health and well-being
Openalex Percentile: Top 1%
Diabetes Treatment and Management
19.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.